BACKGROUND: Factors contributing to either "complete" or "clinical" remission of asthma are important to know since there is no cure for the disease. METHODS: A cohort of 119 allergic asthmatic children was examined three times with a mean follow up of 30 years. They were aged 5-14 years at visit 1 (1966-9), 21-33 years at visit 2 (1983-6), and 32-42 years at visit 3 (1995-6). Complete remission of asthma at visit 3 was defined as no asthma symptoms, no use of inhaled corticosteroids, normal lung function (FEV1 >90% predicted), and no bronchial hyperresponsiveness (PC10 >16 mg/ml). Clinical remission was defined as no asthma symptoms and no use of inhaled corticosteroids. RESULTS: 22% of the group was in complete remission of asthma at visit 3 and a further 30% was in clinical remission (total 52%); 57% of subjects in clinical remission had bronchial hyperresponsiveness and/or a low lung function. Logistic regression analyses showed that a higher FEV1 in childhood and more improvement in FEV1 from age 5-14 to 21-33 were associated with both complete and clinical asthma remission at age 32-42. CONCLUSIONS: Complete remission of asthma was present in a small subset of asthmatics while half the subjects showed clinical remission. Both complete and clinical remission were associated with a higher lung function level in childhood and a higher subsequent increase in FEV1. These results support the view that defining remission only on the basis of symptoms and medication use will overlook subjects with subclinical active disease and possibly associated airway remodelling.
BACKGROUND: Factors contributing to either "complete" or "clinical" remission of asthma are important to know since there is no cure for the disease. METHODS: A cohort of 119 allergic asthmatic children was examined three times with a mean follow up of 30 years. They were aged 5-14 years at visit 1 (1966-9), 21-33 years at visit 2 (1983-6), and 32-42 years at visit 3 (1995-6). Complete remission of asthma at visit 3 was defined as no asthma symptoms, no use of inhaled corticosteroids, normal lung function (FEV1 >90% predicted), and no bronchial hyperresponsiveness (PC10 >16 mg/ml). Clinical remission was defined as no asthma symptoms and no use of inhaled corticosteroids. RESULTS: 22% of the group was in complete remission of asthma at visit 3 and a further 30% was in clinical remission (total 52%); 57% of subjects in clinical remission had bronchial hyperresponsiveness and/or a low lung function. Logistic regression analyses showed that a higher FEV1 in childhood and more improvement in FEV1 from age 5-14 to 21-33 were associated with both complete and clinical asthma remission at age 32-42. CONCLUSIONS: Complete remission of asthma was present in a small subset of asthmatics while half the subjects showed clinical remission. Both complete and clinical remission were associated with a higher lung function level in childhood and a higher subsequent increase in FEV1. These results support the view that defining remission only on the basis of symptoms and medication use will overlook subjects with subclinical active disease and possibly associated airway remodelling.
Authors: D J Godden; S Ross; M Abdalla; D McMurray; A Douglas; D Oldman; J A Friend; J S Legge; J G Douglas Journal: Am J Respir Crit Care Med Date: 1994-01 Impact factor: 21.405
Authors: Wayne J Morgan; Debra A Stern; Duane L Sherrill; Stefano Guerra; Catharine J Holberg; Theresa W Guilbert; Lynn M Taussig; Anne L Wright; Fernando D Martinez Journal: Am J Respir Crit Care Med Date: 2005-08-18 Impact factor: 21.405
Authors: Gregory S Sawicki; Robert C Strunk; Brooke Schuemann; Robert Annett; Scott Weiss; Anne L Fuhlbrigge Journal: Ann Allergy Asthma Immunol Date: 2010-01 Impact factor: 6.347
Authors: Robyn T Cohen; Anusha Madadi; Morey A Blinder; Michael R DeBaun; Robert C Strunk; Joshua J Field Journal: Am J Hematol Date: 2011-08-02 Impact factor: 10.047
Authors: Joanna Smolonska; Gerard H Koppelman; Cisca Wijmenga; Judith M Vonk; Pieter Zanen; Marcel Bruinenberg; Ivan Curjuric; Medea Imboden; Gian-Andri Thun; Lude Franke; Nicole M Probst-Hensch; Peter Nürnberg; Roland A Riemersma; Constant P van Schayck; Daan W Loth; Guy G Brusselle; Bruno H Stricker; Albert Hofman; André G Uitterlinden; Lies Lahousse; Stephanie J London; Laura R Loehr; Ani Manichaikul; R Graham Barr; Kathleen M Donohue; Stephen S Rich; Peter Pare; Yohan Bossé; Ke Hao; Maarten van den Berge; Harry J M Groen; Jan-Willem J Lammers; Willem Mali; H Marike Boezen; Dirkje S Postma Journal: Eur Respir J Date: 2014-07-03 Impact factor: 16.671